A review of human vaccine research and development: Malaria

Girard, Marc; Reed, Zarifah; Friede, Martin; Kiény, Marie Paule

doi:10.1016/j.vaccine.2006.09.074

Cited by 116 publications

(90 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The blood stage antigen AMA1 and the sexual stage antigen Pfs25 are two leading malarial vaccine candidates of Plasmodium falciparum [1,2]. Enhancing the immunogenicities of these antigens to obtain a protective and sustained response in humans remains a formidable task that confronts malarial vaccine researchers today [3,4].…”

Section: Introductionmentioning

confidence: 99%

Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders

Qian

Rausch

Muratova

et al. 2008

Vaccine

View full text Add to dashboard Cite

Both the blood stage protein apical membrane antigen 1 (AMA1) and the 25 kDa sexual stage protein (Pfs25) of Plasmodium falciparum are two leading candidates in malarial vaccine development. We have previously demonstrated that conjugation of these malarial antigens to recombinant Pseudomonas aeruginosa ExoProtein A (rEPA) significantly increased the mean specific functional antibody responses in mice; however, some mice responded poorly and were unable to demonstrate a functional response. We hypothesized that the immunogenicities of these two malarial antigens could be further enhanced by inclusion of a CpG oligodeoxynucleotide in the formulation. Mice were immunized with either rEPA conjugated or unconjugated AMA1 and Pfs25 formulated on Alhydrogel with or without the addition of CPG 7909. Mice received the formulations on days 0 and 28, and mouse sera were collected on day 42. ELISA analyses on these sera showed that the addition of CPG 7909 to AMA1-rEPA and Pfs25-rEPA formulated on Alhydrogel induced significantly higher mean antibody titers than the formulations without CPG 7909, and led to a mixed Th1/Th2 response as demonstrated by the production of mouse IgG1 and IgG2a subclasses. The presence of CPG 7909 in the formulations of both conjugated antigens greatly increased the proportion of responders with antibody titers sufficient to inhibit blood-stage parasite growth in vitro or block transmission of sexual stage parasites to mosquitoes. The results obtained in this study indicate the potential use of a combination strategy to increase the number of responders to malarial antigens in humans.

show abstract

Section: Introductionmentioning

confidence: 99%

Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders

Qian

Rausch

Muratova

et al. 2008

Vaccine

View full text Add to dashboard Cite

show abstract

“…Furthermore, resistance has been identified as a factor that economically compromises malaria control efforts (Trape et al 2002). Great effort and time have been dedicated to the in vitro reproduction of the erythrocytic stages of the Plasmodium life cycle as a fundamental tool for studying the mechanisms of susceptibility and resistance to drugs as well as screening for the identification of new drugs (Girard et al 2007).…”

mentioning

confidence: 99%

In vitro susceptibility of Plasmodium falciparum Welch field isolates to infusions prepared from Artemisia annua L. cultivated in the Brazilian Amazon

Silva

Magalhães

Costa

et al. 2012

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…has a complex life cycle consisting of distinct phases (7), such as asexual (pre-erythrocytic and erythrocytic in humans), and sexual (in mosquito). The life cycle starts when a female mosquito, while feeding on the blood of a healthy individual, injects sporozoites of Plasmodium into the body (24).…”

Section: Approaches To Malaria Vaccine Developmentmentioning

confidence: 99%

“…Pre-erythrocytic vaccines play an important role in protecting against malaria infection and provide, in best cases, sterilising humoral immunity by eliciting antibodies that target the invading sporozoites and preventing them from invading the liver (24). …”

Section: Vaccines Targeting Pre-erythrocytic Asexual Stage Antigensmentioning

confidence: 99%

“…Insufficient clinical trial capacity and normative research functions such as local ethical committee reviews contribute to slow down malaria vaccine development process (24). Africa led and/or owned institutions and networks concerned with malaria vaccine research and development such as the African Malaria Network Trust (AMANET) are needed in good number with offices in all endemic nations of Africa.…”

Section: Programmatic and Operational Challenges For Africa Systems Cmentioning

confidence: 99%

See 1 more Smart Citation

Malaria Vaccine Development: A Challenge for Africa

Unyene¹

2013

IOSR-JDMS

View full text Add to dashboard Cite

A review of human vaccine research and development: Malaria

Cited by 116 publications

References 156 publications

Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders

Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders

In vitro susceptibility of Plasmodium falciparum Welch field isolates to infusions prepared from Artemisia annua L. cultivated in the Brazilian Amazon

Malaria Vaccine Development: A Challenge for Africa

Contact Info

Product

Resources

About